Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MicroRNA Panel Distinguishes Between High- and Low-Risk Pancreatic Lesions

By LabMedica International staff writers
Posted on 15 Feb 2015
Print article
Image: Intraductal papillary mucinous neoplasm (IPMN) in magnetic resonance imaging (Photo courtesy of Wikimedia Commons).
Image: Intraductal papillary mucinous neoplasm (IPMN) in magnetic resonance imaging (Photo courtesy of Wikimedia Commons).
A panel of six microRNAs (miRNAs) has been identified that can distinguish between high-risk and low-risk pancreatic lesions that are capable of progressing to full-blown cancer of the pancreas.

Intraductal papillary mucinous neoplasms (IPMNs) are precursors of the form of cancer of the pancreas called pancreatic ductal adenocarcinoma (PDAC). Differentiating between high-risk IPMNs that warrant surgical resection and low-risk IPMNs that can be monitored has been a significant clinical problem.

Pancreatic cancer is the fourth most common cause of cancer death in the Western world. The prognosis is poor, with one- and five-year survival rates of only 20% and 6%, respectively. To aid in early detection of pancreatic cancer, investigators at the Moffitt Cancer Center (Tampa, FL, USA) used advanced genomic tools to analyze the miRNAs associated with low-risk and high-risk IPMNs.

MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

The investigators performed genome-wide miRNA expression profiling on 28 surgically-resected, pathologically-confirmed IPMNs (19 high-risk, nine low-risk) using Life Technologies (Carlsbad, CA, USA) Taqman MicroRNA Arrays. A validation phase was performed in 21 independent IPMNs (13 high-risk, 8 low-risk). They also explored associations between miRNA expression level and various clinical and pathological factors and examined genes and pathways regulated by the identified miRNAs by integrating data from bioinformatic analyses and microarray analysis of miRNA gene targets.

Results revealed that six miRNAs (miR-100, miR-99b, miR-99a, miR-342-3p, miR-126, miR-130a) were downregulated in high-risk versus low-risk IPMNs and distinguished between these groups. The same trend was observed in the validation phase of the study. Low miR-99b expression was associated with main pancreatic duct involvement, and serum albumin levels were positively correlated with miR-99a and miR-100 expression.

“Importantly, this research may also help foster the development of new prevention and early detection strategies for pancreatic cancer,” said senior author Dr. Mokenge P. Malafa, chairman of the department of gastrointestinal oncology at the Moffitt Cancer Center. “We also provided evidence that the six microRNAs may contribute to pancreatic cancer progression.”

Related Links:

Moffitt Cancer Center
Life Technologies


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.